← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
University Of Kansas Medical C
$0
Total funding
5
Grants
Funding mix
By agency
NIH$0 · 5
By mechanism
N01$0 · 5
Investigators at University Of Kansas Medical C
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
A PHASE I NONRANDOMIZED STUDY OF AN ANTIESTROGEN IN WOMEN WITH NEWLY D-261985035$0
N01 · FY2003 · CA
WS#76 A STUDY TO IDENTIFY BIOMARKER MODULATION BY CYCLOOXYGENASE-2 (CO-261015135$0
N01 · FY2003 · CA
PHASE 1 MULTIPLE-DOSE SAFETY, PHARMACOKINETIC, AND DRUG INTERACTION CL-261035008$0
N01 · FY2003 · CA
PHASE I SINGLE AND MULTIPLE-DOSE SAFETY AND PHARMACO- KINETIC CLINIC-261955121$0
N01 · FY2003 · CA
PHASE I SINGLE AND MULTIPLE DOSE SAFETY, PHARMACOKINETIC-261975035$0
N01 · FY2003 · CA
WS#76 A STUDY TO IDENTIFY BIOMARKER MODULATION BY CYCLOOXYGENASE-2 (CO-261015135$0
N01 · FY2002 · CA
PHASE I SINGLE AND MULTIPLE-DOSE SAFETY AND PHARMACO- KINETIC CLINIC-261955121$0
N01 · FY2002 · CA
PHASE I SINGLE AND MULTIPLE DOSE SAFETY, PHARMACOKINETIC-261975035$0
N01 · FY2002 · CA
A PHASE I NONRANDOMIZED STUDY OF AN ANTIESTROGEN IN WOMEN WITH NEWLY D-261985035$0
N01 · FY2002 · CA